To Evaluate the Safety and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

  • days left to enroll
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 25 May 2021


The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.

Condition Advanced Malignancies
Treatment Parsaclisib
Clinical Study IdentifierNCT04831996
SponsorIncyte Corporation
Last Modified on25 May 2021


Yes No Not Sure

Inclusion Criteria

Participants will be classified at screening by renal function based on eGFR as calculated by the MDRD formula and requirement for HD (Group 5)
Participants eligible for Group 5 with ESRD have received HD for at least 3 months prior to screening
Participants eligible for Group 1 should be in good health as determined by no clinically significant deviations from normal for medical history, physical examination, vital signs, 12-lead ECGs, or clinical laboratory determinations at screening or Day -1
Participants eligible for Groups 2 through 5 may have medical findings consistent with their degree of renal dysfunction
Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible
Body mass index within the range 18.0 to 40.0 kg/m2 (inclusive) at screening
Willingness to avoid pregnancy or fathering children
Ability to swallow and retain oral medication

Exclusion Criteria

History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening. Evidence of rapidly deteriorating renal function
Participants who have a current, functioning organ transplant or have a scheduled organ transplant within 6 weeks after check-in
History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer
History of clinically significant gastrointestinal disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug
Participants eligible for Group 1 who have a history of renal disease or renal injury as indicated by an abnormal, clinically significant renal function profile at screening or Day -1
Participants eligible for Groups 2 through 5 who have had a change in disease status within 30 days of screening, as documented by the participant's medical history, deemed clinically significant by the investigator
History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study
Any major surgery within 4 weeks of screening
Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only)
Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1, Day
(Group 5)
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
Positive test for HBV (HBsAg, HBsAg antibody, and hepatitis B core antibody), HCV (HCV antibody), or HIV. Participants whose results are compatible with prior immunization for HBV may be included at the discretion of the investigator
Participants eligible for Group 1 who have used tobacco- or nicotine-
containing products within 6 months of screening
Participants eligible for Groups 2 through 5 who smoke > 10 cigarettes per day or equivalent use of other tobacco- or nicotine-containing products and are unwilling to refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions
Positive breath test for ethanol or positive urine or serum screen for drugs of abuse that is not otherwise explained by permitted concomitant medications
Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another investigational medication or current enrollment in another investigational drug study
Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with strong or moderate inducer or inhibitor of CYP3A4, P-gp,or BCRP
For participants eligible for Group 1, use of prescription drugs within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional paracetamol, ibuprofen, and standard-dose vitamins are permitted
For participants eligible for Groups 2 through 5, use of prescription drugs within 14 days of study drug administration, with the exception of established therapy for renal disease and the treatment of associated disorders that have been stable for at least 7 days prior to study drug administration, as approved by the investigator and in consultation with the sponsor's medical monitor
Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics. Current clinically significant viral infection at screening or check-in
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator
Inability to undergo venipuncture or tolerate venous access
Participants eligible for Group 5 that are not expected to continue HD treatment for the duration of the study
Receipt of live (including attenuated) vaccines or anticipation of need for such a vaccine during the study (Note: nonlive or inactivated vaccines are allowed up to 2 weeks prior to the first dose of study drug)
Known hypersensitivity or severe reaction to parsaclisib or excipients of parsaclisib
History of alcoholism within 3 months of screening
Women who are pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note